3Lyras D,O'connor JR, Howarth PM, et al. Toxin B is es- sential for virulence of clostridium difficile. Nature, 2009, 458(7) 11176 1179.
4Mullan N, Hughes KR, Mahida YR. Primary human colonic myofibroblasts are resistant to clostridium difficile toxin A- induced, but not toxin B-induced, cell death. Infect Immun, 2011,79(4) .. 1623-1630.
5Gotteland M,Cruchet S, Verbeke S. Effect of lactobacillus ingestion on the gastrointestinal mucosal barrier altera- tions induced by indometacin in humans. Aliment Phaema- col Ther,2011,15 (1) .. 11-17.
6Weber SC, Uhlenberg B, Raile K, Querfeld U, Mtlller D. Polyoma virus-associated progressive multifocal leukoencephalopathy after renal transplantation: regression following withdrawal of mycophenolate mofetil. Pediatr Transplant ,2011, 15:E19-E24 [PMID: 20880091 IX)I: 10.1111/j.1399-3046.2010.01368.x].
7Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD. Mycophenolate mofetil versus enteric- coated mycophenolate sodium: a large, single-cen- ter comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation ,2010, 89:446-451 [PMID: 20177347 DOE 10.1097/ TP.0b013e3181ca860d].
8Ekberg H, van Gelder T, Kaplan B, Bernasconi C. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal func- tion after renal transplantation. Transplantation ,2011, 92:82-87 [PMID: 21562449 DOI: 10.1097/ TP.0b013e31821fad06].
9Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management [ J ]. Nat Rev Gastroenterol Hepatol, 2011,1(8) :17-26.
10Kamboj M, Khosa P, Kaltsas A, et al. Relapse versus reinfection: surveillance of clostridium difficile infection [ J 1. Clin Infect Dis, 2011,53 (10) : 1003-1006.
